For several decades, insulin has been the most reliable treatment strategy and the gold standard in the management of GDM. Metformin is an effective insulin sensitizing agent and an established first line drug for the treatment of type 2 diabetes. Since it crosses the placenta, a safety issue remains an obstacle for its use in the treatment of GDM. However, given emerging data of metformin compared to insulin, it appears that it may open a rather new door in the management of GDM.
During this interview, Dr Linda Barbour will tell us more about the safety and efficacy data of metformin in GDM, potential benefits and side-effects, how it compares to insulin in the treatment of GDM, and the key discoveries of her latest research in this field.
Dr Richard Ross answers our questions about his talk on Endocrine Replacement in Cancer Survivors during the Study Day of the Irish Endocrine and International Society of Endocrinology Symposium 2019.
He tells us about his latest research, what he learned during the Study Day, and how he envisions the future in this research area.